|Title:||Compounds, formulations, and methods for treating or preventing inflammatory skin disorders|
|Abstract:||In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.|
|Inventor(s):||DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)|
|Assignee:||Galderma Laboratories, L.P. (Fort Worth, TX)|
|Filing Date:||Feb 25, 2013|
|Claims:||1. A method of treating an inflammatory skin disorder and symptoms associated therewith, comprising topically administering to the skin of a patient in need of such treatment a composition comprising: a therapeutically effective amount of brimonidine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein the inflammatory skin disorder is not rosacea. |
2. The method according to claim 1, wherein the at least one compound is administered in an amount sufficient to decrease blood flow through the small arteries or arterioles of the skin of the patient.
3. The method according to claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions.
4. The method according to claim 1, wherein the composition acts locally in the skin of the patient.